Table 2.
The actual sample size for each immune status group
| CIS group 11 | CIS group 22 | Non-CIS group3 | Total | |
|---|---|---|---|---|
| HZ | 509 | 4,760 | 6,233 | 11,502 |
| Inpatients4 | 34 | 654 | 1,735 | 2,423 |
| Outpatients4 | 475 | 4,106 | 4,498 | 9,079 |
| PHN | 90 | 1,119 | 1,155 | 2,364 |
| Inpatients4 | 6 | 100 | 222 | 328 |
| Outpatients4 | 84 | 1,019 | 933 | 2,036 |
HZ, herpes zoster; CIS, compromised immune status; PHN, postherpetic neuralgia.
1
Includes patients primarily diagnosed with severe CIS such as transplantation, hematological malignancies, or autoimmune deficiency disease.
2
Includes those who were not in CIS group 1 and diagnosed with mild or moderate CIS such as rheumatoid arthritis, a solid tumor, or diabetes.
3
Includes those who were not included in CIS groups 1 or 2.
4
In this stratified sample of the Korean population, a different sampling probability was applied to those who were hospitalized (13%) and those never hospitalized but who visited an outpatient clinic at least once (1%).